What is the share price of Granules India Ltd (GRANULES) today?
The share price of GRANULES as on 25th June 2025 is ₹496.65. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Granules India Ltd (GRANULES) share?
The past returns of Granules India Ltd (GRANULES) share are- Past 1 week: -3.70%
- Past 1 month: -4.19%
- Past 3 months: -4.35%
- Past 6 months: -18.04%
- Past 1 year: 0.33%
- Past 3 years: 90.54%
- Past 5 years: 136.79%
What are the peers or stocks similar to Granules India Ltd (GRANULES)?
The peers or stocks similar to Granules India Ltd (GRANULES) include:What is the dividend yield % of Granules India Ltd (GRANULES) share?
The current dividend yield of Granules India Ltd (GRANULES) is 0.30.What is the market cap of Granules India Ltd (GRANULES) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Granules India Ltd (GRANULES) is ₹12065.46 Cr as of 25th June 2025.What is the 52 week high and low of Granules India Ltd (GRANULES) share?
The 52-week high of Granules India Ltd (GRANULES) is ₹721 and the 52-week low is ₹422.What is the PE and PB ratio of Granules India Ltd (GRANULES) stock?
The P/E (price-to-earnings) ratio of Granules India Ltd (GRANULES) is 24.06. The P/B (price-to-book) ratio is 3.74.Which sector does Granules India Ltd (GRANULES) belong to?
Granules India Ltd (GRANULES) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Granules India Ltd (GRANULES) shares?
You can directly buy Granules India Ltd (GRANULES) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Granules India Ltd
GRANULES Share Price
GRANULES Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GRANULES Performance & Key Metrics
GRANULES Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
24.06 | 3.74 | 0.30% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
35.49 | 6.52 | 0.85% |
from 8 analysts
Price Upside
Earnings Growth
Rev. Growth
GRANULES Company Profile
Granules India Limited is a pharmaceutical company that manufactures finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).
GRANULES Forecast
GRANULES Forecasts
Price
Revenue
Earnings
GRANULES Share Price Forecast
GRANULES Share Price Forecast
All values in ₹
All values in ₹
GRANULES Company Revenue Forecast
GRANULES Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
GRANULES Stock EPS (Earnings Per Share) Forecast
GRANULES Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
GRANULES
GRANULES
Income
Balance Sheet
Cash Flow
GRANULES Income Statement
GRANULES Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,445.21 | 1,711.45 | 2,354.63 | 2,688.44 | 3,264.42 | 3,782.53 | 4,525.70 | 4,510.77 | 4,525.28 | 4,525.27 | ||||||||||
Raw Materials | 679.96 | 902.90 | 1,338.97 | 1,314.92 | 1,590.28 | 2,036.42 | 2,352.65 | 2,208.22 | 3,536.37 | 3,536.38 | ||||||||||
Power & Fuel Cost | 38.67 | 48.22 | 57.68 | 59.74 | 68.85 | 74.66 | 95.69 | 100.64 | ||||||||||||
Employee Cost | 140.19 | 165.21 | 209.82 | 259.04 | 324.29 | 366.44 | 420.35 | 550.24 | ||||||||||||
Selling & Administrative Expenses | 174.70 | 216.04 | 262.58 | 313.30 | 427.22 | 521.25 | 580.83 | 696.63 | ||||||||||||
Operating & Other expenses | 78.21 | 73.83 | 26.11 | 126.33 | -28.32 | 43.92 | 148.57 | 94.66 | ||||||||||||
EBITDA | 333.48 | 305.25 | 459.47 | 615.11 | 882.10 | 739.84 | 927.61 | 860.38 | 988.91 | 988.89 | ||||||||||
Depreciation/Amortization | 71.51 | 76.20 | 105.48 | 136.95 | 151.46 | 158.63 | 184.49 | 207.33 | 225.50 | 225.50 | ||||||||||
PBIT | 261.97 | 229.05 | 353.99 | 478.16 | 730.64 | 581.21 | 743.12 | 653.05 | 763.41 | 763.39 | ||||||||||
Interest & Other Items | 32.26 | 33.06 | 28.46 | 27.02 | 26.28 | 23.21 | 55.93 | 105.82 | 103.24 | 103.24 | ||||||||||
PBT | 229.71 | 195.99 | 325.53 | 451.14 | 704.36 | 558.00 | 687.19 | 547.23 | 660.17 | 660.15 | ||||||||||
Taxes & Other Items | 65.20 | 63.40 | 89.11 | 115.73 | 154.90 | 145.25 | 170.58 | 141.92 | 158.65 | 158.65 | ||||||||||
Net Income | 164.51 | 132.59 | 236.42 | 335.41 | 549.46 | 412.75 | 516.61 | 405.31 | 501.52 | 501.50 | ||||||||||
EPS | 7.39 | 5.50 | 9.31 | 13.19 | 21.89 | 16.65 | 21.08 | 16.73 | 20.69 | 20.69 | ||||||||||
DPS | 0.90 | 1.00 | 1.00 | 1.00 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | ||||||||||
Payout ratio | 0.12 | 0.18 | 0.11 | 0.08 | 0.07 | 0.09 | 0.07 | 0.09 | 0.07 | 0.07 |
GRANULES Company Updates
Investor Presentation
GRANULES Stock Peers
GRANULES Past Performance & Peer Comparison
GRANULES Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Granules India Ltd | 24.06 | 3.74 | 0.30% |
Sun Pharmaceutical Industries Ltd | 36.50 | 5.94 | 0.96% |
Cipla Ltd | 22.97 | 4.52 | 1.07% |
Dr Reddy's Laboratories Ltd | 19.39 | 3.88 | 0.61% |
GRANULES Stock Price Comparison
Compare GRANULES with any stock or ETFGRANULES Holdings
GRANULES Shareholdings
GRANULES Promoter Holdings Trend
GRANULES Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
GRANULES Institutional Holdings Trend
GRANULES Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
GRANULES Shareholding Pattern
GRANULES Shareholding Pattern
GRANULES Shareholding History
GRANULES Shareholding History
Mutual Funds Invested in GRANULES
Mutual Funds Invested in GRANULES
No mutual funds holding trends are available
Top 5 Mutual Funds holding Granules India Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1718% | Percentage of the fund’s portfolio invested in the stock 2.29% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/88 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0993% | Percentage of the fund’s portfolio invested in the stock 1.04% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 47/156 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7605% | Percentage of the fund’s portfolio invested in the stock 1.18% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/138 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing GRANULES stock
smallcases containing GRANULES stock
Looks like this stock is not in any smallcase yet.
GRANULES Events
GRANULES Events
GRANULES Dividend Trend
GRANULES has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.30%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.01 every year
Dividends
Corp. Actions
Announcements
Legal Orders
GRANULES Dividend Trend
GRANULES has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.30%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.01 every year
GRANULES Upcoming Dividends
GRANULES Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 31, 2025
Dividend/Share
₹1.50
Ex DateEx Date
Jul 31, 2025
GRANULES Past Dividends
GRANULES Past Dividends
Cash Dividend
Ex DateEx DateJul 30, 2024
Dividend/Share
₹1.50
Ex DateEx Date
Jul 30, 2024
Cash Dividend
Ex DateEx DateAug 3, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Aug 3, 2023
Cash Dividend
Ex DateEx DateJul 19, 2022
Dividend/Share
₹0.75
Ex DateEx Date
Jul 19, 2022
Cash Dividend
Ex DateEx DateFeb 17, 2022
Dividend/Share
₹0.25
Ex DateEx Date
Feb 17, 2022
Cash Dividend
Ex DateEx DateNov 24, 2021
Dividend/Share
₹0.25
Ex DateEx Date
Nov 24, 2021
GRANULES Stock News & Opinions
GRANULES Stock News & Opinions
In a regulatory filing, the company stated that the USFDA conducted the inspection from 16 June to 20 June 2025. At the conclusion of the inspection, the USFDA issued a Form 483 with one observation. The company stated that it will respond to this observation within the stipulated time frame. The Bonthapally facility is one of the world's largest single-site paracetamol API manufacturing plants by volume. Along with paracetamol APIs, the company has also established metformin and guaifenesin API manufacturing units at the same site. The official announcement was made on 20 June 2025, after market hours. Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company's consolidated net profit rose by 17.3% to Rs 152.03 crore, on a 2.4% increase in total revenue from operations to Rs 1,196.82 crore in Q4 FY25, compared to Q4 FY24. The counter rose 0.31% to Rs 488.35 on the BSE. Powered by Capital Market - Live
Granules India has approved the allotment of 1,00,000 equity shares in consequence of the exercise of stock options under ESOS 2009.Powered by Capital Market - Live
Granules India announced that Krishnamohan B., shall to be the Senior Management Personnel (SMP) of the Company upon his resignation from the position of Vice President & Head- IT with effect from the closure of business hours of 02 June 2025. Powered by Capital Market - Live
Net profit of Granules India rose 17.26% to Rs 152.03 crore in the quarter ended March 2025 as against Rs 129.65 crore during the previous quarter ended March 2024. Sales rose 2.37% to Rs 1196.82 crore in the quarter ended March 2025 as against Rs 1169.06 crore during the previous quarter ended March 2024. For the full year,net profit rose 23.74% to Rs 501.52 crore in the year ended March 2025 as against Rs 405.31 crore during the previous year ended March 2024. Sales declined 0.76% to Rs 4455.97 crore in the year ended March 2025 as against Rs 4490.16 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1196.821169.06 2 4455.974490.16 -1 OPM %21.0921.87 -21.2119.06 - PBDT230.30228.82 1 854.92754.56 13 PBT166.80175.64 -5 629.42547.23 15 NP152.03129.65 17 501.52405.31 24 Powered by Capital Market - Live
Granules India announced that the Board of Directors of the Company at its meeting held on 28 May 2025, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 150%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Granules India announced that the 34th Annual General Meeting(AGM) of the company will be held on 7 August 2025.Powered by Capital Market - Live
Net profit of Granules India declined 3.26% to Rs 94.05 crore in the quarter ended March 2025 as against Rs 97.22 crore during the previous quarter ended March 2024. Sales declined 21.75% to Rs 730.46 crore in the quarter ended March 2025 as against Rs 933.47 crore during the previous quarter ended March 2024. For the full year,net profit declined 26.74% to Rs 319.34 crore in the year ended March 2025 as against Rs 435.92 crore during the previous year ended March 2024. Sales declined 20.66% to Rs 2967.57 crore in the year ended March 2025 as against Rs 3740.13 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales730.46933.47 -22 2967.573740.13 -21 OPM %16.0020.28 -19.0321.43 - PBDT133.91172.93 -23 542.71735.15 -26 PBT95.94136.52 -30 396.48591.30 -33 NP94.0597.22 -3 319.34435.92 -27 Powered by Capital Market - Live
Granules India will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live
Granules India announced the successful closing of the acquisition of Senn Chemicals AG, a Swiss based Contract Development and Manufacturing Organization (CDMO) specializing in peptide development and manufacturing. This marks a strategic milestone in Granules' transformation into a science- and innovation-led organization and extends its capabilities into the fast growing peptide therapeutics segment. The acquisition follows the signing of a definitive share purchase agreement in February 2025, under which Granules, through its wholly owned Indian subsidiary, Granules Peptides, acquired 100% of the equity of Senn Chemicals from the founding Senn family. Founded over 60 years ago, Senn Chemicals has built a strong reputation as a specialist in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), serving innovators and brand owners across pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. Powered by Capital Market - Live
Granules India has allotted 50,000 equity shares under ESOS on 20 March 2025. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.88%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 1.07% to 1.18%
Over the last 5 years, net income has grown at a yearly rate of 11.38%, vs industry avg of 15.29%